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Edited by Hans-Dieter KlenkAbstract We developed a reverse genetics system of hepatitis C
virus (HCV) genotypes 1a and 2a using infectious clones and
human hepatocyte chimeric mice. We inoculated cell culture-
produced genotype 2a (JFH-1) HCV intravenously. We also in-
jected genotype 1a CV-H77C clone RNA intrahepatically. Mice
inoculated with HCV by both procedures developed measurable
and transmissible viremia. Interferon (IFN) alpha treatment re-
sulted in greater reduction of genotype 2a HCV levels than geno-
type 1a, as seen in clinical practice. Genetically engineered HCV
infection system should be useful for analysis of the mechanisms
of resistance of HCV to IFN and other drugs.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The hepatitis C virus (HCV) infects an estimated 170 million
people worldwide [1]. HCV causes persistent infection in adults
leading to chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma [2,3]. The most eﬀective therapy for viral clearance
is a 48-week combination therapy of pegylated interferon
(IFN)-alpha and ribavirin. However, the success rate of thisAbbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HSA,
human serum albumin; IFN, interferon; SCID, severe combined
immunodeﬁciency; uPA, urokinase-type plasminogen activator
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new anti-HCV drug had been severely restricted by the absence
of a cell culture system that supports the eﬃcient replication of
HCV, as well as the lack of a small animal model. A cell cul-
ture system has been developed recently using a unique geno-
type 2a HCV gnome (JFH-1), which does not require adaptive
mutations for eﬃcient replication [5–7]. Chimpanzee was the
only useful animal for the study of HCV until recently,
although the availability of this model is severely restricted
[8]. Recently, HCV-infected mice have been developed
by inoculating HCV-infected human serum into chimeric
urokinase-type plasminogen activator (uPA)-severe combined
immunodeﬁciency (SCID) mice with engrafted human hepato-
cytes [9]. This HCV-infected mouse model has been reported to
be useful for evaluating anti-HCV drugs such as IFN-alpha
and anti-NS3 protease [10]. We have generated a human hepa-
tocyte chimeric mouse where mouse hepatocytes were exten-
sively replaced by human hepatocytes [11], and established a
genetically engineered hepatitis B virus (HBV) system [12].
Using this mouse, we show in this paper the development of
reverse genetics system of genotypes 1a and 2a after intrahe-
patic injection of transcribed RNA and intravenous injection
of cell culture-produced virus, respectively. We also show here
that HCV in these mice can be transmitted to naı¨ve mice.
Interferon treatment of these mice resulted in a greater reduc-
tion of HCV titer in genotype 2a clone infected mice than in
genotype 1a infected mice. As these results are consistent with
our clinical experience, we consider this model suitable for the
study of resistance of HCV against IFN and other drugs.2. Materials and methods
2.1. Generation of human hepatocyte chimeric mice and quantiﬁcation
of human serum albumin
Generation of the uPA+/+/SCID+/+ mice and transplantation of
human hepatocytes were performed as described recently by our group
[11,12]. All mice used in this study were transplanted with frozenblished by Elsevier B.V. All rights reserved.
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serum samples, and sacriﬁce were performed under ether anesthesia.
Mouse serum concentrations of human serum albumin (HSA) corre-
late with the repopulation index [11], and were measured as described
previously [12]. The experimental protocol was approved by the Ethics
Review Committee for Animal Experimentation of Graduate School
of Biomedical Sciences, Hiroshima University.Fig. 1. Serial changes in HCV RNA and human serum albumin in sera
of mice inoculated with human serum samples positive for genotype 1b
HCV. Fifty microliter serum samples were injected intravenously into2.2. HCV RNA transcription and inoculation into chimeric mice
A plasmid containing the full-length genotype 1a HCV cDNA clone,
pCV-H77C, was kindly provided by Dr. Robert H. Purcell (National
Institutes of Health). Ten micrograms of plasmid DNA, linearized
by XbaI (Promega, Madison, WI) digestion, was transcribed in a
100-ll reaction volume with T7 RNA polymerase (Promega) at
37 C for 2 h [13], and analyzed by agarose gel electrophoresis. Each
transcription mixture was diluted with 400 ll of phosphate-buﬀered
saline (PBS) and injected into the liver of chimeric mice. Transcripts
of plasmid pJFH-1 containing the full-length HCV genotype 2a were
transfected into Huh7 cells as described previously [6]. Seventy-two
hours after transfection, 200 ll of the culture medium was injected
intravenously into the chimeric mice. IFN-treatment was also per-
formed by intramuscular injection of diluted IFN solutions. IFN-alpha
was a kind gift from Hayashibara Biochemical Labs, Inc. (Okayama,
Japan). Serum samples collected every 2 weeks after inoculation were
frozen at 80 C until further analysis.each mouse. Mice serum samples were obtained every 2 weeks after
injection, and HCV RNA titer was analyzed.2.3. Human serum samples
For control infection experiments, human serum containing a high
titer of genotype 1b HCV (2.2 · 106 copies/ml) was obtained from a
patient with chronic hepatitis after obtaining a written informed con-
sent. The individual serum samples were divided into small aliquots
and separately stored in liquid nitrogen until use.
2.4. RNA extraction and ampliﬁcation
RNA was extracted from serum samples by Sepa Gene RV-R
(Sankojunyaku, Tokyo), dissolved in 8.8 ll RNase-free H2O, and re-
verse transcribed by using a random primer (Takara Bio, Inc., Shiga,
Japan) and M-MLV reverse transcriptase (ReverTra Ace, TOYOBO
Co., Osaka, Japan) in a 20 ll reaction mixture according to the instruc-
tions provided by the manufacturer. One microliter of cDNA solution
was ampliﬁed by Light Cycler (Roche Diagnostic, Japan, Tokyo) for
quantitation of HCV. The primers used for ampliﬁcation were
5 0-TTTATCCAAGAAAGGACCC-30 and 5 0-TTCACGCAGAAAG-
CGTCTAGC-3 0. The ampliﬁcation conditions included initial dena-
turation at 95 C for 10 min, followed by 45 cycles of denaturation
at 95 C for 15 s, annealing at 55 C for 5 s, and extension at 72 C
for 6 s. The lower detection limit of this assay is 103 copies/ml. Nested
PCR was used with the outer primers NC1 (5 0-CAACACTACTCGG-
CTAGCAGT-3 0) and NC2 (5 0-CCTGTGAGGAACTACTGTC-30)
and inner primers cc6 (5 0-TTTATCCAAGAAAGGACCC-30) and
cc7 (5 0-TTCACGCAGAAAGCGTCTAGCttc-3 0). The ampliﬁcation
condition included 35 cycles of 94 C for 30 s, 58 C for 1 min 30 s,
and 72 C for 1 min after 5 min of initial denaturation at 94 C fol-
lowed by 7 min of ﬁnal extension using Gene Taq (Wako Pure Chem-
icals, Tokyo) with anti-Taq high according to the instructions provided
by the manufacturer (TOYOBO).2.5. Histochemical analysis of mouse liver
Histopathological analysis and immunohistochemical staining using
an antibody against HSA (Bethyl Laboratories Inc.) were performed as
described previously [12].3. Results
3.1. High serum HCV RNA titer in human hepatocyte chimeric
mice after inoculation of serum samples obtained from
HCV-infected patient
We inoculated 50 ll of genotype 1b serum samples into ﬁve
chimeric mice intravenously to test their susceptibility to HCV
infection. All mice became positive for HCV RNA by nestedPCR at 2 weeks after inoculation (Fig. 1). The viremia reached
a plateau level at 6–8 weeks after infection, and persisted for
more than 12 weeks.3.2. Infection with in vitro-transcribed genotype 1a HCV RNA
and cell culture generated genotype 2a HCV
In the next step, we tried to establish infection of cloned
HCV using infectious genotype 1a and genotype 2a clones.
In these experiments, we used two diﬀerent strategies to estab-
lish infection using these two clones because genotype 1a has
not been conﬁrmed to replicate in cell culture system. We used
genotype 1a HCV RNA (CV-H77C), which has been reported
to be infectious to chimpanzee [13]. In vitro-transcribed HCV
RNA was directly injected intrahepatically in three chimeric
mice. We also infected three chimeric mice by intravenous
injection of Huh7 cell-produced genotype 2a HCV after trans-
fection of in vitro transcribed RNA from an infectious clone
JFH-1. This clone has been shown to be infectious to a chim-
panzee [6] and a chimeric mouse [7]. All mice developed mea-
surable viremia 2 weeks after inoculation. At 6 weeks after
inoculation, HCV RNA titer was 2.4 · 107 copies/ml (range:
8.8 · 106–2.9 · 107 copies/ml) in genotype 1a HCV-infected
mice, and 2.5 · 105 copies/ml (range: 1.4 · 105–3.7 · 105 cop-
ies/ml) in genotype 2a HCV-infected mice (Fig. 2).3.3. Passage experiment of HCV to naı¨ve chimeric mice
We then performed passage experiments using naı¨ve mice.
Each of three mice was inoculated intravenously with 10 ll ser-
um samples obtained from the above genotype 1a and geno-
type 2a HCV-infected mice at week 6. Two weeks after
injection, all mice developed measurable viremia, and the titer
was 8.5 · 106 copies/ml (range: 1.4 · 106–2.4 · 107 copies/ml)
in genotype 1a, and 1.7 · 105 copies/ml (range: 1.5 · 105–
2.5 · 105 copies/ml) in genotype 2a HCV-infected mice
(Fig. 3).
Fig. 2. Changes in HCV RNA and human albumin concentrations in
serum of mice infected with clonal HCV. Each of three mice were
inoculated intrahepatically with in vitro transcribed genotype 1a HCV
RNA (closed circles) or intravenously with a culture medium collected
from Huh7 cells transfected with JFH-1 genome intravenously (open
circles). Data are mean ± S.D.
Fig. 3. Passage experiment and response to IFN-alpha therapy in mice
infected with HCV genotypes 1a and 2a clones. Serum samples (10 ll)
obtained from genotype 1a and 2a clonal HCV-infected mice sera (see
Fig. 2) were inoculated intravenously into each of three naı¨ve chimeric
mice. Six weeks after infection, all six mice were injected intramuscu-
larly with 1000 IU/g/day of IFN-alpha daily for 2 weeks. Closed
circles: genotype 1a HCV-infected mice, open circles: genotype 2a
HCV-infected mice. Data are mean ± S.D.
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We treated each of the three mice infected with genotype 1a
and 2a clones by passage experiments with 1000 IU/g of IFN-
alpha daily for 2 weeks. Such treatment induced only a slight
decrease in HCV in genotype 1a-infected mice; the viral load
decreased only 0.6 and 0.7 log after 1 and 2 weeks of treat-
ment, respectively (Fig. 3). In contrast, the same treatment re-Fig. 4. Histochemical analysis of the tissues of infected chimeric mice. Liv
genotype 2a (B, D) stained with hematoxylin–eosin staining (A, B) or by im
(C, D). Regions are shown as human (H) and mouse (M) hepatocytes, respeduced HCV genotype 2a RNA to undetectable levels after 1
and 2 weeks of IFN therapy. During IFN-treatment, serum
HSA levels did not decrease in mice infected with genotype
1a or 2a HCV. Histopathological examination showed no
morphological changes or apoptotic hepatocytes in replaceder samples obtained from mice infected with genotype 1a (A, C) and
munohistochemical staining with anti-human serum albumin antibody
ctively. (Original magniﬁcation, ·100.)
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2-week IFN-treatment (Fig. 4). These results suggest that the
decrease in HCV is due to the direct anti-viral eﬀect of IFN
and not induced by liver cell damage. The diﬀerence in the
virus titer and susceptibility to IFN are considered to be due
to the characteristics of the genotypes.4. Discussion
In this study, we established a reverse genetics system of
HCV genotype 1a and 2a clones using human hepatocyte chi-
meric mice. The HCV genotype 2a clone, JFH-1, has remark-
able features, i.e., infects cultured Huh7 cell line as well as
establish infection in chimeric mouse [7]. It has been reported
that HCV genotype 1a clone, H77-S, also infects Huh7 cell line
and produces infectious virion [14]. In the present study, we
intrahepatically inoculated genotype 1a infectious clone, CV-
H77C. As reported in chimpanzee [13,15–17], we were able
to establish genotype 1a infection using human hepatocyte chi-
meric mice. Using this technique, it is hoped that we can con-
duct further experiments in the future using genetically
engineered HCV clones. Experiments using chimeric clone de-
scribed by Lindenbach et al. [7] should also provide further
information regarding the variable replication property of
HCV genomes. Modifying genomes with nucleotide substitu-
tions allowed examination of the functions of HCV peptides
as we showed with HBV [12].
As reported recently by Kneteman et al. [10], the mouse
model system is useful for evaluating the eﬀect of anti-HCV
drugs such as IFN, protease inhibitors and polymerase inhib-
itors. As we showed in this study, the response to IFN therapy
varied according to HCV genotype. Further experiments are
necessary to determine whether diﬀerences in response to
IFN are due to the diﬀerent replication ability (replication level
of genotype 2a clone was slightly lower than that of genotype
1b, see Figs. 2 and 3) or diﬀerences in genotypes, as has been
reported in clinical studies [18]. As we showed in this study
(Fig. 4), there is no hepatocyte damage or inﬂammation in
the liver of the infected chimeric mouse. Thus, this model is
suitable for the study of mechanisms involved in HCV replica-
tion and IFN resistance.
The intrahepatic injection method used in this study simpli-
ﬁed our experiments using genetically engineered virus. This is
particularly important in studies of protease inhibitors and
polymerase inhibitors because HCV will easily develop resis-
tance against these small molecule agents.
Previous studies identiﬁed amino acid sequences that corre-
late with diﬀerent susceptibilities of genotype 1b HCV against
IFN therapy, namely, interferon sensitivity determining region
[19] and the PKR-eIF2 phosphorylation homology domain
[20,21]. To elucidate such issues, we are currently trying to
establish genotype 1b infection system using the method de-
scribed in this paper.
In summary, we showed in the present study the successful
application of a genetically engineered HCV in human hepato-
cyte chimeric mice. Using this mouse model, we showed that
genotypes 1a and 2a HCV clones exhibit diﬀerent susceptibili-
ties to IFN-alpha therapy. Our mouse model seems useful for
the study of HCV virology and resistance of HCV against IFN
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